Sequenced CAR-Technology

SequencedCAR™ Platform

Precision In-Vivo CAR-T Engineering Through Programmable Two-Step Delivery

The Problem

Current approaches to CAR-T therapy require harvesting a patient’s T cells, engineering them in a centralised manufacturing facility, and re-infusing them days to weeks later — a process that is expensive, logistically fragile, and inaccessible to most patients worldwide. Emerging in-vivo CAR-T approaches attempt to solve this by delivering CAR genes directly inside the body, but they face a critical limitation: they cannot reliably distinguish between the T cells they should engineer and the T cells they should not.

Engineering regulatory T cells alongside effector T cells risks undermining the very immune response the therapy is designed to activate. Without cell-type selectivity, in-vivo CAR-T remains a promising concept constrained by an unresolved safety and efficacy concern.

Our Approach

SequencedCAR™ is a proprietary two-infusion system that generates CAR-T cells inside the patient's body with a level of cell-type precision not achievable by single-vector approaches.

The first infusion delivers a non-integrating genetic construct designed to selectively mark only effector T cells. This step does not permanently modify the genome and does not affect regulatory T cells.

The second infusion delivers an engineered viral particle equipped with targeting elements that specifically recognise the Mark placed in the first step — directing CAR gene integration exclusively to the pre-marked effector T cell population.

The result is a system where only the intended cell population receives the CAR construct, and where gene expression is linked to the T cell’s activation state — reducing the risks of tonic signalling and premature exhaustion that limit current approaches.

Key Platform Features

Effector T Cell Selectivity

Designed to engineer only effector T cells while leaving regulatory T cells unmodified — addressing a core safety limitation of current in-vivo CAR-T strategies.

Non-Integrating First Step

The initial construct does not integrate into the genome, confining permanent genetic modification to the precisely targeted second infusion.

Modular Second Infusion

The anchor-based recognition system allows the same first infusion to be paired with different second infusions carrying different CAR constructs — one preparation step, multiple therapeutic targets.

Activation-Responsive Expression

CAR gene expression is coupled to T cell activation, reducing off-target activity and mitigating the chronic signalling that drives T cell exhaustion.

Platform Scalability

Eliminates the need for ex vivo manufacturing, leukapheresis, and patient-specific production — enabling a pathway toward off-the-shelf in-vivo CAR-T therapy.

Clinical Potential & Pipeline Application

SequencedCAR™ forms the delivery backbone for Endurion’s lead pipeline programmes, including GX-01 (Ariflex™, Anti-CD19 CAR-T) and GX-02 (Anti-BCMA CAR-T). The modular architecture of the platform is designed to support rapid expansion into additional antigen targets without requiring fundamental changes to the delivery system.

By removing the manufacturing bottleneck inherent in ex vivo CAR-T production, SequencedCAR™ is designed to reduce time-to-treatment, lower cost-of-goods, and expand patient access — particularly in settings where centralised cell manufacturing infrastructure is unavailable.

“Precision without the factory. SequencedCAR™ engineers CAR-T cells where they are needed most — inside the patient.”